|
US6756038B1
(en)
*
|
1997-10-10 |
2004-06-29 |
The United States Of America As Represented By The Department Of Health And Human Services |
Agonist and antagonist peptides of carcinoembryonic antigen (CEA)
|
|
DE10048710A1
(de)
*
|
1999-09-27 |
2001-10-04 |
Gabriele Pecher |
Pharmazeutische Zusammensetzung zur Behandlung und Prophylaxe von humanen Tumoren, die das Tumorantigen Muzin und/oder das Carcinoembryonale Antigen (CEA) exprimieren und ihre Verwendung
|
|
CA2388337C
(en)
*
|
1999-10-22 |
2013-01-08 |
Aventis Pasteur Limited |
Method of inducing and/or enhancing an immune response to tumor antigens
|
|
US7179462B2
(en)
|
2000-06-02 |
2007-02-20 |
University Of Connecticut Health Center |
α (2) macroglobulin receptor as a heat shock protein receptor and uses thereof
|
|
EP1286693A4
(en)
|
2000-06-02 |
2005-07-13 |
Univ Connecticut Health Ct |
COMPLEXES OF ALPHA (2) MACROGLOBULIN AND ANTIGENIC MOLECULES FOR USE IN IMMUNOTHERAPY
|
|
US7186515B1
(en)
|
2000-06-02 |
2007-03-06 |
University Of Connecticut Health Center |
Alpha(2) macroglobulin receptor as a heat shock protein receptor and uses thereof
|
|
EP1305414A2
(en)
*
|
2000-07-31 |
2003-05-02 |
Aventis Pasteur Limited |
Modified cea and uses thereof
|
|
WO2002018954A2
(en)
|
2000-08-30 |
2002-03-07 |
Chemocentryx, Inc. |
Inhibition of cmv infection and dissemination
|
|
EP2336339A3
(en)
|
2000-09-25 |
2011-09-14 |
The Regents of the University of Michigan |
Production of viral vectors
|
|
CA2437201C
(en)
|
2001-02-02 |
2008-11-18 |
Chemocentryx, Inc. |
Methods and compositions useful for stimulating an immune response
|
|
WO2003008537A2
(en)
*
|
2001-04-06 |
2003-01-30 |
Mannkind Corporation |
Epitope sequences
|
|
US7414032B2
(en)
|
2001-06-25 |
2008-08-19 |
Immunofrontier, Inc. |
Vaccine comprising a polynucleotide encoding an antigen recognized by a CD4+ helper T-cell and a polynucleotide encoding a tumor specific or associated antigen recognized by a CD8+ CTL
|
|
KR101455222B1
(ko)
|
2002-12-16 |
2014-10-31 |
글로브이뮨 |
면역 요법으로서의 효모계 백신
|
|
JP2007503834A
(ja)
*
|
2003-09-05 |
2007-03-01 |
サノフィ パストゥール リミテッド |
黒色腫用の多抗原ベクター
|
|
CA2550583C
(en)
*
|
2003-10-08 |
2013-01-15 |
Sanofi Pasteur, Inc. |
Modified cea /b7 vector
|
|
WO2005046622A2
(en)
|
2003-11-12 |
2005-05-26 |
Therion Biologics Corporation |
Custom vectors for treating and preventing pancreatic cancer
|
|
DK1694364T3
(da)
*
|
2003-11-12 |
2014-07-21 |
Us Government |
System til behandling og forebyggelse af brystcancer
|
|
WO2005068640A2
(en)
*
|
2003-12-23 |
2005-07-28 |
Aventis Pasteur, Inc. |
Modified ksa and uses thereof
|
|
WO2006004362A1
(en)
*
|
2004-07-03 |
2006-01-12 |
Mogam Biotechnology Research Institute |
Supertype epitopes, oligonucleotides coding the same which induce effective ctl response against hcv and the use thereof
|
|
US7785875B2
(en)
|
2004-07-03 |
2010-08-31 |
Mogam Biotechnology Research Institute |
Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same
|
|
ES2313807B1
(es)
*
|
2005-07-30 |
2009-12-23 |
Consejo Superior De Investigaciones Cientificas |
Vectores recombinantes basados en el virus vaccinia modificado de ankara (mva) como vacunas contra la leishmaniasis.
|
|
EP1792996A1
(en)
*
|
2005-12-01 |
2007-06-06 |
Consejo Superior de Investigaciones Cientificas |
Nucleic acid sequences encoding vaccines against Porcine reproductive and respiratory syndrome virus (PRRSV)
|
|
SI2856876T1
(en)
|
2007-03-30 |
2018-04-30 |
Memorial Sloan-Kettering Cancer Center |
Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
|
|
DK2170384T3
(en)
|
2007-07-02 |
2016-07-25 |
Etubics Corp |
METHODS AND COMPOSITIONS FOR THE PRODUCTION OF AN adenovirus vector for use in higher vaccination
|
|
AU2008312444B2
(en)
*
|
2007-10-18 |
2014-02-06 |
Bavarian Nordic A/S |
Use of MVA to treat prostate cancer
|
|
WO2010042433A1
(en)
|
2008-10-06 |
2010-04-15 |
Bristol-Myers Squibb Company |
Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
|
|
US8691502B2
(en)
|
2008-10-31 |
2014-04-08 |
Tremrx, Inc. |
T-cell vaccination with viral vectors via mechanical epidermal disruption
|
|
WO2010050913A1
(en)
*
|
2008-10-31 |
2010-05-06 |
The Brigham And Women's Hospital, Inc. |
Vaccination with poxvirus vectors via mechanical epidermal disruption
|
|
MX2011010977A
(es)
|
2009-04-17 |
2012-02-29 |
Us Health |
Composiciones inmunoterapeuticas combinadas contra cancer y metodos.
|
|
SG10201607663YA
(en)
|
2011-08-17 |
2016-11-29 |
Globeimmune Inc |
Yeast-muc1 immunotherapeutic compositions and uses thereof
|
|
US9605276B2
(en)
|
2012-08-24 |
2017-03-28 |
Etubics Corporation |
Replication defective adenovirus vector in vaccination
|
|
CA2914790C
(en)
|
2013-06-14 |
2024-02-27 |
Psioxus Therapeutics Limited |
A dosing regime and formulations for type b adenoviruses
|
|
HUE035875T2
(hu)
|
2013-10-25 |
2018-06-28 |
Psioxus Therapeutics Ltd |
Heterológ géneket tartalmazó onkolitikus adenovírusok
|
|
UA127337C2
(uk)
*
|
2013-11-28 |
2023-07-26 |
Баваріан Нордік А/С |
Рекомбінантний поксвірус для індукції посиленої імунної відповіді та його застосування
|
|
JP5917626B2
(ja)
*
|
2014-07-28 |
2016-05-18 |
トレムアールエックス， インコーポレイテッド |
機械的表皮破壊を介したポックスウイルスベクターによるワクチン接種
|
|
CN107406857B
(zh)
*
|
2015-01-09 |
2021-06-29 |
埃图比克斯公司 |
用于联合免疫治疗的方法和组合物
|
|
AU2016205208A1
(en)
|
2015-01-09 |
2017-07-06 |
Etubics Corporation |
Methods and compositions for ebola virus vaccination
|
|
US11149087B2
(en)
|
2015-04-20 |
2021-10-19 |
Etubics Corporation |
Methods and compositions for combination immunotherapy
|
|
HRP20200439T1
(hr)
|
2015-04-30 |
2020-06-12 |
Psioxus Therapeutics Limited |
Onkolitički adenovirus koji kodira protein b7
|
|
BR112018012180A2
(pt)
|
2015-12-17 |
2018-12-04 |
Psioxus Therapeutics Ltd |
vírus de codificação de um anticorpo ou fragmento de complexo anti-tcr
|
|
CN109312364A
(zh)
*
|
2016-03-18 |
2019-02-05 |
河谷细胞有限公司 |
用于感染树突状细胞的多模式载体
|
|
CN109890408A
(zh)
*
|
2016-05-27 |
2019-06-14 |
埃特彼塞斯公司 |
新表位疫苗组合物及其使用方法
|
|
GB201713765D0
(en)
|
2017-08-28 |
2017-10-11 |
Psioxus Therapeutics Ltd |
Modified adenovirus
|
|
IL303187A
(en)
|
2016-08-29 |
2023-07-01 |
Akamis Bio Ltd |
Adenovirus with bispecific T cell activator
|
|
CA3092860A1
(en)
*
|
2018-03-06 |
2019-09-12 |
Pepvax, Inc. |
Nucleic acid molecules and methods of using the same
|
|
US20210290708A1
(en)
|
2018-09-21 |
2021-09-23 |
Nantcell, Inc. |
Methods and compositions for modulating myeloid-derived suppressor cells
|
|
GB202010095D0
(en)
*
|
2020-07-01 |
2020-08-12 |
Tcer Ab |
Immunotherapy
|